William Duke - Pulmatrix Insider

PULM -- USA Stock  

USD 0.49  0.0002  0.041%

Mr. William E. Duke, Jr., is the Chief Financial Officer of Pulmatrix, Inc. Prior to joining our company, Mr. Duke served as the chief financial officer of Valeritas, a medical technology company, from January 2014 until June 2015 and from July 2011 until January 2014, he served as Valeritass Vice President and Corporationrationrate Controller. At Valeritas, Mr. Duke led the controller relationship, financial planning and analysis, investor relations and information technology functions. Prior to joining Valeritas, Mr. Duke was Senior Director, Finance for Genzyme Corporationrationration, a biopharmaceutical company, from January 2010 to July 2011, where he had oversight responsibility for external reporting to the Securities and Exchange Commission, internal management reporting and worldwide financial consolidation. Prior to Genzyme, he was the Director of Finance and Accounting of Haemonetics Corporationrationration, a medical device company, from May 2008 to January 2010 and held various senior financial roles with consulting services and emerging growth organizations
Age: 42  CFO Since 2015  MBA    
781-357-2333  http://pulmatrix.com
Duke holds a B.S. in Accounting from Stonehill College and a M.B.A. with a concentration in Finance from Bentley University and is a Certified Public Accountant.

William Duke Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (65.98) % which means that it has lost $65.98 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (168.96) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 2.52 M in liabilities with Debt to Equity (D/E) ratio of 33.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pulmatrix has Current Ratio of 0.32 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Entity Summary

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 24 people.Pulmatrix (PULM) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 24 people. Pulmatrix was previously known as PULMATRIX INC and was traded on BATS Exchange under the symbol RTGN. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.

Pulmatrix Leadership Team

Terrance McGuire, Director
Matthew Sherman, Director
David Hava, Chief Scientific Officer
Akihisa Akao, Director
James Roach, Chief Medical Officer
Michael Higgins, Director
Steven Gillis, Director
Jean Sung, Vice President - Pharmaceutical Development
William Duke, CFO, Principal Financial Officer & Principal Accounting Officer
Robert Clarke, CEO and President and Director
Scott Rocklage, Director
Kurt Graves, Director
Richard Conley, Independent Director
Mark Iwicki, Chairman of the Board
Amit Munshi, Director
Gregory French, Independent Director
David JD, Advisor

Stock Performance Indicators

Did you try this?

Run World Markets Correlation Now

World Markets Correlation

Find global opportunities by holding instruments from different markets
All  Next Launch World Markets Correlation
Currently Active Assets on Macroaxis
Purchased over 20 shares of
2 days ago
Traded for 106.27
Purchased over 200 shares of
2 days ago
Traded for 10.56
Purchased over 70 shares of
2 days ago
Traded for 39.4
Purchased few shares of
2 days ago
Traded for 1184.91
Purchased over 40 shares of
2 days ago
Traded for 69.22
Additionally take a look at Your Equity Center. Please also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. macroaxis watchlist is based on self-learning algorithm to remember stocks you like.